Vik Anders, Helbekkmo Nina, Bremnes Roy M
Medisinsk avdeling, Regionsykehuset i Tromsø 9038 Tromsø.
Tidsskr Nor Laegeforen. 2002 Jan 20;122(2):165-9.
We present a study of treatment outcome and evaluate pre-treatment prognostic factors in patients treated for low-grade non-Hodgkin's lymphoma (LG-NHL) at our institution during a ten-year period.
169 consecutively registered patients from 1986 to 1996 were retrospectively analysed with regard to demographic, treatment, and disease-specific characteristics. Median follow-up time was 52 months. All patients were diagnosed histologically according to the previous Kiel classification system. Median age was 60 years; the male:female ratio was 1.05:1.
The response rate was 66%; median overall survival 8.3 years. Five and ten-year overall survival were 72% and 47% respectively. For stage 1, 2, 3 and 4, ten-year overall survival were 86%, 65%, 33% and 29%. Of the pre-treatment parameters, advanced stage, B-symptoms, poor performance status, bone marrow infiltration, tumour > or = 6 cm, low serum albumin, anaemia, and LD > or = 540 U/l were all related to survival. According to the multivariate analysis, stage, performance status, tumour size, and anaemia were found to be independent prognostic factors for overall survival.
The strategy of radiation therapy has proved successful for most patients with stage 1 disease. Independent prognostic factors for overall survival such as stage, performance status, tumour size, and anaemia may be useful guides in deciding when and how to treat.
我们开展了一项关于治疗结果的研究,并评估了在我们机构接受治疗的低度非霍奇金淋巴瘤(LG-NHL)患者的治疗前预后因素,研究为期十年。
对1986年至1996年间连续登记的169例患者进行回顾性分析,内容涉及人口统计学、治疗及疾病特异性特征。中位随访时间为52个月。所有患者均根据先前的基尔分类系统进行组织学诊断。中位年龄为60岁;男女比例为1.05:1。
缓解率为66%;中位总生存期为8.3年。五年和十年总生存率分别为72%和47%。对于Ⅰ期、Ⅱ期、Ⅲ期和Ⅳ期,十年总生存率分别为86%、65%、33%和29%。在治疗前参数中,晚期、B症状、体能状态差、骨髓浸润、肿瘤≥6 cm、低血清白蛋白、贫血和乳酸脱氢酶≥540 U/L均与生存相关。根据多变量分析,分期、体能状态、肿瘤大小和贫血被发现是总生存的独立预后因素。
放疗策略已被证明对大多数Ⅰ期疾病患者是成功的。总生存的独立预后因素,如分期、体能状态、肿瘤大小和贫血,可能有助于指导治疗时机和治疗方式的决策。